GTAM
IBO

Global Trust Asset Management’s Impact BioMedical IBO Stock Holding History

Global Trust Asset Management’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$836 Hold
1,818
– – ﹤0.01% 441
2026
Q1 		$1.09K Buy
+1,818
New +$909 ﹤0.01% 431

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Global Trust Asset Management's IBO Position: Q2 2026 in Review

Global Trust Asset Management held its Impact BioMedical (IBO) position steady in Q2 2026 at 1,818 shares worth $836. The position accounts for ﹤0.01% of the portfolio, ranked #441.

Global Trust Asset Management first reported a position in IBO in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.09K in Q1 2026. 22 funds tracked by Wall St. Rank hold IBO as of Q2 2026.

  • Global Trust Asset Management held 1,818 shares of Impact BioMedical worth $836 as of Q2 2026.
  • Global Trust Asset Management left its Impact BioMedical share count unchanged in Q2 2026.
  • Impact BioMedical made up ﹤0.01% of Global Trust Asset Management's portfolio in Q2 2026, its #441 holding.
  • Global Trust Asset Management first reported a position in Impact BioMedical in Q1 2026 and has held it in 2 quarters since.
  • Global Trust Asset Management's Impact BioMedical position peaked at $1.09K in Q1 2026.
  • 22 funds tracked by Wall St. Rank held Impact BioMedical as of Q2 2026.

Based on Global Trust Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.